Table 2:

Total economic burden^* of fungal diseases, United States

		Indirect costs due to productivity loss
Disease	Total direct medical costs	From workdays lost due to hospitalizations	From workdays lost due to outpatient visits	From premature deaths	Total economic burden
Aspergillosis	$2,028,442,227	$101,596,045	$3,568,606	$615,165,702	$2,748,772,580
Blastomycosis	$82,975,143	$5,918,846	$4,398,263	$49,777,981	$143,070,232
Candida infection	$4,259,657,979	$291,966,352	$235,022,700	$1,104,396,539	$5,891,043,570
Invasive or severe candidiasis	$4,329,051,014	$284,760,493	$6,466,774	$656,950,542	$5,277,228,824
Non-invasive/unspecified candidiasis	$1,008,652,811	$3,917,419	$260,796,154	$376,100,073	$1,649,466,457
Coccidioidomycosis	$645,919,784	$46,493,269	$54,023,590	$141,941,614	$888,378,257
Cryptococcosis	$370,489,540	$33,590,311	$983,997	$304,575,033	$709,638,882
Dermatophytosis (ringworm) and other superficial mycoses	$1,270,737,246	$629,810	$653,414,214	†	$1,924,781,270
Histoplasmosis	$299,994,242	$22,080,742	$49,253,393	$132,505,839	$503,834,216
Pneumocystis pneumonia	$679,408,224	$55,481,945	$1,124,735	$482,296,135	$1,218,311,039
Mucormycosis	$622,042,667	$16,075,282	$563,981	$197,982,608	$836,664,537
Other and unspecified mycoses	$3,107,315,255	$130,654,240	$5,601,278	$1,257,746,774	$4,501,317,546
Total	$13,366,982,307	$704,486,842	$1,007,954,756	$4,286,388,225	$19,365,812,130

^*In 2024 dollars.

^†Not calculated because no in-hospital deaths due to dermatophytosis occurred.